eligibility_summary
Adults (KPS≥60) with measurable GBM. Arm1/Safety: recurrent EGFRvIII+ at first relapse, prior RT, MGMT any. Arm2: newly dx EGFRvIII+, MGMT unmethylated, planned RT alone, must complete ≥75% of 6-wk RT pre-infusion. Arm3: first-recurrent EGFRvIII– with EGFR amp. All: Ommaya, dex ≤4 mg/d, adequate organs, LVEF>50%, >3‑mo prognosis, contraception. LMD allowed. Exclude posterior fossa or spine-only, prior EGFRvIII/gene therapy, active HIV/HBV/HCV, chronic immunosuppression, pregnancy.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Trial NCT05660369 tests CARv3-TEAM-E T cells in glioblastoma. Intervention: autologous, lentivirally transduced CAR T-cell therapy delivered intraventricularly via Ommaya. Mechanism: the CAR (CARv3) recognizes EGFRvIII on GBM cells, activating the infused T cells, the cells also secrete a T-cell–engaging antibody molecule (TEAM-E), an EGFR×CD3 bispecific that recruits and activates endogenous T cells to attack EGFR/EGFR-amplified tumor cells, aiming to prevent antigen escape. Targets: tumor cells expressing EGFRvIII and EGFR (including EGFR-amplified GBM), immune activation via CD3 on T cells, EGFR/EGFRvIII-driven oncogenic pathway. Arms include recurrent/newly diagnosed EGFRvIII+ GBM and recurrent EGFRvIII− but EGFR-amplified GBM.